US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

1:48U.S.Marineswiththe26thMarineExpeditionaryUnit(SpecialOperationsCapable)’s(MEU(SOC))MaritimeSpeci AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri




Wikipedia

author：comprehensive    Page View：4112
Adobe

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

advertisement

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Flash flooding emergencies prompt evacuations in Kentucky, Tennessee
Next article： George Santos makes 1st court appearance after pleading not guilty to 13 counts